BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang X, Yuan T, Dong H, Xu J, Wang D, Tong H, Ji X, Sun B, Zhu M, Jiang X. Novel block glycopolymers prepared as delivery nanocarriers for controlled release of bortezomib. Colloid Polym Sci 2018;296:1827-39. [PMID: 30416246 DOI: 10.1007/s00396-018-4406-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Allahyari S, Valizadeh H, Zakeri-milani P. Polymeric Nanoparticles and Their Novel Modifications for Targeted Delivery of Bortezomib. Pharm Sci 2020;26:363-9. [DOI: 10.34172/ps.2020.21] [Reference Citation Analysis]
2 Kwon S, Kim KB, Yeo Y, Lee W. Pharmacokinetic aspects of the clinically used proteasome inhibitor drugs and efforts toward nanoparticulate delivery systems. J Pharm Investig 2021;51:483-502. [DOI: 10.1007/s40005-021-00532-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Korani M, Korani S, Zendehdel E, Nikpoor AR, Jaafari MR, Orafai HM, Johnston TP, Sahebkar A. Enhancing the Therapeutic Efficacy of Bortezomib in Cancer Therapy Using Polymeric Nanostructures. CPD 2020;25:4883-92. [DOI: 10.2174/1381612825666191106150018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Jafari F, Yilmaz G, Becer CR. Stimuli-responsive glycopolymers and their biological applications. European Polymer Journal 2021;142:110147. [DOI: 10.1016/j.eurpolymj.2020.110147] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]